Exagen Inc. Expands Coverage with MediNcrease
June 09 2022 - 8:25AM
Exagen Inc. (Nasdaq: XGN), a leading provider of
autoimmune testing solutions, announced today the addition of
Exagen Inc. to MediNcrease Health Plans, LLC’s national provider
network, providing enhanced care to their approximately 7.5 million
commercial lives. The agreement, effective July 1, 2022, with
MediNcrease will make AVISE® tests, including AVISE® Lupus and
AVISE® CTD accessible through MediNcrease’s client base of regional
and national health plans, insurance companies, employers,
municipalities, third-party administrators, unions, and other
companies involved in the management of medical claims.
"Our partnership with MediNcrease is an exciting
step forward. This partnership will provide the client base,
members, and providers of MediNcrease Health Plans, access to a
timely and accurate differential diagnosis for complex autoimmune
diseases, including Systemic Lupus Erythematosus (SLE)," said Ron
Rocca, Exagen’s President and CEO. "SLE is a complex autoimmune
disease, and the earlier a diagnosis is reached the better chance a
patient has to prevent irreversible organ damage."
"We are thrilled to welcome Exagen to the
MediNcrease provider network," said Linda Plaster, Managing Partner
of MediNcrease Health Plans. "This exciting relationship affirms
continued commitment to our specialty lab network expansion and
increasing the accessibility of specialized diagnostic testing
solutions."
About Exagen Inc.
Exagen (Nasdaq: XGN) is a leading provider of
autoimmune diagnostic, prognostic, and monitoring testing
solutions. Exagen is a patient focused, discovery driven
organization built on the success of AVISE testing and is investing
in its product pipeline to support patients throughout their
autoimmune diagnosis and treatment journeys. Exagen’s goal is to
assist patients, physicians, and payors by enabling precision
medicine. Exagen is located in San Diego
County with clinical and research and development laboratories
in Vista, CA.
For more information, please
visit Exagen.com and follow @ExagenInc on
Twitter.
About MediNcrease Health Plans
MediNcrease is a uniquely positioned national
provider network and provider advocacy firm servicing the
commercial health, workers’ compensation, and auto medical markets.
Its advanced provider network and negotiation solutions not only
help facilitate millions of dollars in expedited payments to
providers each year, but also provide medical payers with
dramatically improved savings and service over traditional PPO
networks. The result is a 100% defensible and transparent solution
for both providers and payers. For more information, please visit
the company’s website at http://medincrease.com
Forward Looking Statements
Exagen cautions you that statements contained in this press
release regarding matters that are not historical facts are
forward-looking statements. These statements are based on Exagen's
current beliefs and expectations. Such forward-looking statements
include, but are not limited to, statements regarding the expected
benefits of the positive medical policy coverage for AVISE tests
with MediNcrease, including the availability and expected use of
AVISE tests through the MediNcrease network, and any potential for
increased use of AVISE laboratory tests. The inclusion of
forward-looking statements should not be regarded as a
representation by Exagen that any of its plans will be achieved.
Actual results may differ from those set forth in this press
release due to the risks and uncertainties inherent in Exagen’s
business, including, without limitation: the COVID-19 pandemic may
continue to adversely affect its business, financial condition and
results of operations, including as a result of slowdown in its
operations as well as those of its suppliers and courier services,
impeding patient movement and interruptions to healthcare services
causing a decrease in test volumes, disruptions to the supply chain
of material needed for its tests causing an increase on cost per
test, its sales and commercialization activities and its ability to
receive specimens and perform or deliver the results from its
tests, delays in reimbursement and coverage decisions from Medicare
and third-party payors and in interactions with regulatory
authorities, and delays in ongoing and planned clinical trials
involving its tests; Exagen’s commercial success depends upon
attaining and maintaining significant market acceptance of its
testing products and promoted therapeutics among rheumatologists,
patients, third-party payors and others in the medical community;
Exagen’s ability to successfully execute on its business
strategies; third party payors not providing coverage and adequate
reimbursement for Exagen’s testing products or promoted
therapeutics, including Exagen’s ability to collect funds due;
expectations regarding its pipeline products, including the
development of the AVISE RADR platform; Exagen’s ability to obtain
and maintain intellectual property protection for its testing
products; regulatory developments affecting Exagen’s business; and
other risks described in Exagen’s prior press releases and Exagen’s
filings with the Securities and Exchange Commission ("SEC"),
including under the heading "Risk Factors" in Exagen’s Annual
Report on Form 10-K for the year ended December 31, 2021 and any
subsequent filings with the SEC. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date hereof, and Exagen undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date hereof. All forward-looking
statements are qualified in their entirety by this cautionary
statement, which is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995.
Investor RelationsExagen Inc. Ryan
Douglasrdouglas@exagen.com 760.560.1525
CompanyExagen Inc.Kamal Adawi, Chief Financial
Officerkadawi@exagen.com 760.477.5514
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Sep 2023 to Sep 2024